Janssen Presents Updated Data on First-in-Class Talquetamab at ASCO Suggesting Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
Retrieved on:
Monday, May 24, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Health care, Health sciences, Johnson & Johnson, Health, Protein domains, Orphan drugs, Multiple myeloma, B-cell maturation antigen, Cilag, Janssen Pharmaceuticals, Genmab, Takeda Oncology, Talquetamab, Multiple Myeloma, the Janssen Pharmaceutical Companies of Johnson & Johnson, TALQUETAMAB, MULTIPLE MYELOMA, THE JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON
Patients in this study had progressed, had relapsed after, or were refractory to numerous multiple myeloma therapies.
Key Points:
- Patients in this study had progressed, had relapsed after, or were refractory to numerous multiple myeloma therapies.
- As of April 18, 2021, 184 patients with relapsed or refractory multiple myeloma had received talquetamab.
- Janssen Pharmaceutica NV, Janssen Research & Development, LLC, and Janssen-Cilag Limited are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
- Teclistamab and Talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.